Makale

2019 – Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients

Obesity is a well-known carcinogenic factor for colorectal cancer [1, 2]. However, the relationship between obesity and malignancy is still not well understood. Obesity can cause production of VEGF, angiopoietin-2, and other growth factors that induce tumor growth [3, 4]. It can also cause insulin resistance, hyperinsulinemia, and increased production of adipokines and proinflamatory cytokines…

Devamını Oku
Makale

2018 – Plexin C1 Marks Liver Cancer Cells with Epithelial Phenotype and Is Overexpressed in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fifth most common cancer amongman and seventh among woman and ranked as the third most common cause of cancer-related deaths [1, 2]. Chronic liver injury, Hepatitis B (HBV) and C (HCV) virus infections, alcohol-associated diseases, and aflatoxin intoxications are the leading causes of HCC development. Several mutations affecting WNT/𝛽-Catenin, PI3K/RAS,…

Devamını Oku
Makale

2017 – Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Efforts to improve outcomes beyond those achieved with 1 year of trastuzumab in patients with early-stage HER2-positive breast cancer are ongoing. Several different approaches, including extending the duration of trastuzumab to 2 years (HERceptin Adjuvant [HERA] trial),5 concurrent or sequential administration of lapatinib, a tyrosine kinase inhibitor, with trastuzumab (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation…

Devamını Oku
Makale

2016 – Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study

Renal cell carcinoma (RCC) accounts for approximately 2% of all cancers.1 On admission, one-third of patients with RCC are at the metastatic stage.2 Chemotherapy resistance is very high in patients with RCC.3 Only a limited subset of patients ( 20%) benefit from cytokine therapy.4-7 It has been shown that the median progressionfree survival (PFS) was…

Devamını Oku
Makale

2015 – Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial)

Colorectal cancer is among the most common type of cancers worldwide. According to the GLOBOCAN 2008 database, which is published by the International Agency for Research on Cancer to estimate the worldwide incidence and mortality of 27 cancers from 182 countries, colorectal cancer (1.23 million, 9.7% of the total) is the third most commonly diagnosed…

Devamını Oku
Makale

2014 – Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients

Radical cystectomy with pelvic lymphadenectomy has been considered the standard treatment in muscle-invasive bladder cancer patients and 5-year overall survival rates are about 60 %.with this treatment [1] Alternatively, bladderpreserving strategies with maximal transurethral resection of bladder tumor followed by platinum-based chemoradiotherapy has been tested in randomized controlled trials [2–6]. In these studies, the complete…

Devamını Oku